Modelska-Ziółkiewicz Anna, Gembicki Maciej, Sowiński Jerzy
Katedra i Klinika Endokrynologii i Przemiany Materii i Chorób Wewnetrznych AM im. K. Marcinkowskiego w Poznaniu.
Pol Arch Med Wewn. 2003 May;109(5):463-8.
Intercellular adhesion molecule-1 (ICAM-1) and endothelial leukocyte adhesion molecule-1 (ELAM-1) are playing a significant role in an inflammatory process. In patients with autoimmune disorders of thyroid gland an increased expression of ICAM-1 and ELAM-1 was found in thyroid and also in orbital tissue in presence of active ophthalmopathy. Reports concerning concentrations of adhesion molecules soluble forms (sELAM-1 and sICAM-1) in sera of patients suffered from different thyroid gland diseases are controversial. The aim of the project was an estimation of levels of adhesion molecules soluble forms in sera of patients with Graves' disease (GD) and toxic nodular goiter (TNG). In the presented research work sICAM-1 and sELAM-1 were determined in 149 subjects (aged 17-69 years) divided to following groups: group 1--16 hyperthyroid GD patients with active ophthalmopathy (GO) (10 females and 6 males); group 2--25 euthyroid GD patients with GO (17 females and 8 males); group 3--41 hyperthyroid GD patients without GO (22 females and 16 males); group 4--36 patients with TNG (20 females and 16 males) and control group (group 5)--31 healthy subjects (16 females and 16 males). sICAM-1 and sELAM-1 serum concentrations were determined using highly sensitive enzyme linked immunosorbent assay (ELISA). In comparison with control group (group 5) in groups 1--3 significant increase of sICAM-1 and sELAM-1 concentrations was found (p < 0.001). The highest values for both adhesion molecules were demonstrated in the group of hyperthyroid GD patients with GO (group 1) as well as in group of euthyroid GD patients with GO (group 2). In group 1 the values were higher than those in group 2. Lower concentrations were present in group of GD patients with hyperthryroidism without symptoms of GO (group 3). The lowest adhesion molecules concentrations in four examined groups were present in sera of patients with TNG (group 4). The level of sICAM-1 in this group was higher than that in control group, but the difference was not statistically significant (p < 0.01), on the contrary sELAM-1 concentration was markedly elevated in comparison with group 5 (p < 0.002). From the obtained results it may be concluded that elevated sICAM-1 and sELAM-1 concentrations in sera of GD patients are dependent on autoimmunological factors, presence of inflammatory changes in the orbital tissue as well as on hyperthyroidism. Nonautoimmune hyperthyroidism has also influence on increase of sICAM-1 and sELAM-1 levels.
细胞间黏附分子-1（ICAM-1）和内皮白细胞黏附分子-1（ELAM-1）在炎症过程中发挥着重要作用。在患有甲状腺自身免疫性疾病的患者中，发现甲状腺以及存在活动性眼病时的眼眶组织中ICAM-1和ELAM-1的表达增加。关于不同甲状腺疾病患者血清中可溶性黏附分子形式（sELAM-1和sICAM-1）浓度的报道存在争议。该项目的目的是评估格雷夫斯病（GD）和毒性结节性甲状腺肿（TNG）患者血清中可溶性黏附分子形式的水平。在本研究工作中，对149名年龄在17至69岁之间的受试者进行了sICAM-1和sELAM-1的测定，这些受试者分为以下几组：第1组——16名患有活动性眼病（GO）的甲状腺功能亢进GD患者（10名女性和6名男性）；第2组——25名患有GO的甲状腺功能正常GD患者（17名女性和8名男性）；第3组——41名无GO的甲状腺功能亢进GD患者（22名女性和16名男性）；第4组——36名TNG患者（20名女性和16名男性）以及对照组（第5组）——31名健康受试者（16名女性和16名男性）。使用高度敏感的酶联免疫吸附测定（ELISA）法测定血清中sICAM-1和sELAM-1的浓度。与对照组（第5组）相比，第1至3组中sICAM-1和sELAM-1的浓度显著升高（p<0.001）。两种黏附分子的最高值在患有活动性眼病的甲状腺功能亢进GD患者组（第1组）以及患有GO的甲状腺功能正常GD患者组（第2组）中表现出来。第1组的值高于第2组。甲状腺功能亢进且无GO症状的GD患者组（第3组）中的浓度较低。在四个检查组中，TNG患者血清中的黏附分子浓度最低（第4组）。该组中sICAM-1的水平高于对照组，但差异无统计学意义（p<0.01），相反，与第5组相比，sELAM-1的浓度显著升高（p<0.002）。从获得的结果可以得出结论，GD患者血清中sICAM-1和sELAM-1浓度的升高取决于自身免疫因素、眼眶组织中炎症变化的存在以及甲状腺功能亢进。非自身免疫性甲状腺功能亢进也会影响sICAM-1和sELAM-1水平的升高。
